BGOG-ov-41

A phase III randomized, double-blinded trial of platinum-based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal or peritoneal cancer and platinum treatment-free interval (TFIp) >6 months

Sponsor: Grupo Español de Investigación en Cáncer de Ovario (GEICO)

Participating sites:

  • UZ Leuven, Leuven
  • CHU Ambroise Paré, Mons
  • CHU UCL Namur, site Sainte Elisabeth, Namur
  • CHU UCL St. Luc, Bruxelles
  • Grand Hôpital de Charleroi, Charleroi
  • CHU de Liège, site Sart Tilman, Liège